Filamentous fungal biofilm for production of human drug metabolites
Files in This Item:
|Filamentous_fungal_biofilm_for_production_of_human_drug_metabolites_AMB_revision_Feb_2013.pdf||523.5 kB||Adobe PDF||Download|
|Title:||Filamentous fungal biofilm for production of human drug metabolites||Authors:||Amadio, Jessica
Murphy, Cormac D.
|Permanent link:||http://hdl.handle.net/10197/5635||Date:||Jul-2013||Online since:||2014-06-09T14:08:41Z||Abstract:||In drug development, access to drug metabolites is essential for assessment of toxicity and pharmacokinetic studies. Metabolites are usually acquired via chemical synthesis, although biological production is potentially more efficient with fewer waste management issues. A significant problem with the biological approach is the effective half-life of the biocatalyst, which can be resolved by immobilisation. The fungus Cunninghamella elegans is well established as a model of mammalian metabolism, although it has not yet been used to produce metabolites on a large scale. Here, we describe immobilisation of C. elegans as a biofilm, which can transform drugs to important human metabolites. The biofilm was cultivated on hydrophilic microtiter plates and in shake flasks containing a steel spring in contact with the glass. Fluorescence and confocal scanning laser microscopy revealed that the biofilm was composed of a dense network of hyphae, and biochemical analysis demonstrated that the matrix was predominantly polysaccharide. The medium composition was crucial for both biofilm formation and biotransformation of flurbiprofen. In shake flasks, the biofilm transformed 86% of the flurbiprofen added to hydroxylated metabolites within 24 h, which was slightly more than planktonic cultures (76%). The biofilm had a longer effective lifetime than the planktonic cells, which underwent lysis after 2×72 h cycles, and diluting the Sabouraud dextrose broth enabled the thickness of the biofilm to be controlled while retaining transformation efficiency. Thus, C. elegans biofilm has the potential to be applied as a robust biocatalyst for the production of human drug metabolites required for drug development.||Type of material:||Journal Article||Journal:||Applied Microbiology and Biotechnology||Volume:||97||Issue:||13||Start page:||5955||End page:||5963||Copyright (published version):||2013 Springer||Keywords:||Biotransformation; Biocatalysis; Confocal laser scanning microscopy; Fluorine; Zygomycete||DOI:||10.1007/s00253-013-4833-x||Language:||en||Status of Item:||Peer reviewed|
|Appears in Collections:||Biomolecular and Biomedical Science Research Collection|
Show full item record
Page view(s) 5088
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.